Education
About Us
Working with TipRanks
Follow Us
Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
GLUE Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
GLUE Stock 12 Month Forecast
Average Price Target
$18.00
▲(184.36% Upside)
| Highest Price Target$20.00 | Average Price Target$18.00 | Lowest Price Target$16.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Guggenheim
$16
Buy
152.76%
Upside
Reiterated
09/16/25
LifeSci Capital
―
Buy
―
Reiterated
09/15/25
LifeSci Capital Sticks to Their Buy Rating for Monte Rosa Therapeutics (GLUE)This morning, Monte Rosa (Nasdaq: GLUE) announced a second collaboraon agreement with Novars (NYSE: NVS) regarding 1) an exclusive license to an undisclosed discovery target and 2) opons to license two programs from the Company's preclinical immunology porolio. As it relates to the agreement, in today's press release, Monte Rosa added that: "The agreement further strengthens our financial posion, which allows us to progress our wholly owned programs, including mulple undisclosed targets in Th17-driven autoimmune condions, and provides runway beyond mulple ancipated Phase 2 readouts for We'll note that Monte Rosa will receive an upfront payment of $120M from Novars under the terms of the agreement, and that the Company's publicly disclosed pipeline assets (VAV1, NEK7, GSPT1, CDK2/CCNE) are outside the scope of the collaboraon.
TD Cowen
―
Buy
―
Reiterated
09/15/25
Piper Sandler
$20
Buy
215.96%
Upside
Reiterated
07/07/25
Wedbush
$17
Buy
168.56%
Upside
Reiterated
05/09/25
Wells Fargo
$11→$10
Hold
57.98%
Upside
Reiterated
03/20/25
J.P. Morgan
$12
Buy
89.57%
Upside
Reiterated
03/20/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Guggenheim
$16
Buy
152.76%
Upside
Reiterated
09/16/25
LifeSci Capital
―
Buy
―
Reiterated
09/15/25
LifeSci Capital Sticks to Their Buy Rating for Monte Rosa Therapeutics (GLUE)This morning, Monte Rosa (Nasdaq: GLUE) announced a second collaboraon agreement with Novars (NYSE: NVS) regarding 1) an exclusive license to an undisclosed discovery target and 2) opons to license two programs from the Company's preclinical immunology porolio. As it relates to the agreement, in today's press release, Monte Rosa added that: "The agreement further strengthens our financial posion, which allows us to progress our wholly owned programs, including mulple undisclosed targets in Th17-driven autoimmune condions, and provides runway beyond mulple ancipated Phase 2 readouts for We'll note that Monte Rosa will receive an upfront payment of $120M from Novars under the terms of the agreement, and that the Company's publicly disclosed pipeline assets (VAV1, NEK7, GSPT1, CDK2/CCNE) are outside the scope of the collaboraon.
TD Cowen
―
Buy
―
Reiterated
09/15/25
Piper Sandler
$20
Buy
215.96%
Upside
Reiterated
07/07/25
Wedbush
$17
Buy
168.56%
Upside
Reiterated
05/09/25
Wells Fargo
$11→$10
Hold
57.98%
Upside
Reiterated
03/20/25
J.P. Morgan
$12
Buy
89.57%
Upside
Reiterated
03/20/25
Best Analysts Covering Monte Rosa Therapeutics
1 Month
xxx
Success Rate
7/10 ratings generated profit
Average Return
+17.57%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +17.57% per trade.
3 Months
xxx
Success Rate
6/10 ratings generated profit
Average Return
+17.68%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +17.68% per trade.
1 Year
Success Rate
5/10 ratings generated profit
Average Return
+19.33%
reiterated a buy rating 9 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +19.33% per trade.
2 Years
xxx
Success Rate
5/10 ratings generated profit
Average Return
+18.05%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +18.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
GLUE Analyst Recommendation Trends
Rating
Apr 25
May 25
Jul 25
Aug 25
Sep 25
Strong Buy
6
7
3
2
2
Buy
0
2
2
4
4
Hold
6
3
1
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
12
6
6
6
Each month's total comprises the sum of three months' worth of ratings.
GLUE Financial Forecast
GLUE Stock Forecast FAQ
What is GLUE’s average 12-month price target, according to analysts?
Based on analyst ratings, Monte Rosa Therapeutics’s 12-month average price target is 18.00.
What is GLUE’s upside potential, based on the analysts’ average price target?
Monte Rosa Therapeutics has 184.36% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is GLUE a Buy, Sell or Hold?
Monte Rosa Therapeutics has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Monte Rosa Therapeutics’s price target?
The average price target for Monte Rosa Therapeutics is 18.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $16.00. The average price target represents 184.36% Increase from the current price of $6.33.
The highest analyst price target is $20.00 ,the lowest forecast is $16.00. The average price target represents 184.36% Increase from the current price of $6.33.
What do analysts say about Monte Rosa Therapeutics?
Monte Rosa Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of GLUE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.